HR+/HER2- BREAST CANCER: UNLOCKING MARKET POTENTIAL WITH NEW THERAPIES

HR+/HER2- breast cancer is one of the most common subtypes, impacting a large number of patients worldwide. As oncology research advances, new drug candidates are being developed that have the potential to revolutionize HR+/HER2- breast cancer treatment. These innovative therapies aim to enhance efficacy, improve patient outcomes, and reshape mar